Prevention of Chest Pain in Chemo-treated Cancer Patients

Last updated: July 5, 2024
Sponsor: Vejle Hospital
Overall Status: Completed

Phase

N/A

Condition

Angina

Chest Pain

Myocardial Ischemia

Treatment

Cardiologic assessment

Clinical Study ID

NCT03486340
CATCH2018
  • Ages > 18
  • All Genders

Study Summary

This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment prior to the 5-FU treatment. The investigators hypothesize that aggressive management of ischemic risk factors in asymptomatic patients will reduce the number of hospitalisations and investigations for acute coronary syndrome during and after 5-FU treatment and that patients with high coronary artery calcium scores are more likely to experience chest pain during the treatment with 5-FU.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically verified cancer

  • First-time treatment with 5-FU/Capecitabine

  • Expected remaining lifetime > 6 months

  • Informed consent

Exclusion

Exclusion Criteria:

  • Known ischemic heart disease

  • Ischemia-suspicious symptoms prior to 5-FU treatment

  • Ischemia-suspicious ECG-changes prior to 5-FU treatment

Study Design

Total Participants: 218
Treatment Group(s): 1
Primary Treatment: Cardiologic assessment
Phase:
Study Start date:
April 11, 2018
Estimated Completion Date:
June 07, 2024

Connect with a study center

  • Departments of Oncology and Medicine, Vejle Hospital

    Vejle,
    Denmark

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.